Immunic Inc. traded at $3.47 this Friday July 1st, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Immunic Inc. lost 10.51 percent. Over the last 12 months, its price fell by 73.89 percent. Looking ahead, we forecast Immunic Inc. to be priced at 3.38 by the end of this quarter and at 3.11 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Dynavax Technologies 12.96 0.37 2.94% 30.91%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Epizyme 1.48 0.01 0.68% -81.41%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Insmed 20.89 1.17 5.93% -26.70%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Omeros 4.64 1.89 68.73% -69.05%
OraSure Technologies 2.72 0.01 0.37% -73.36%
Quidel 97.11 -0.07 -0.07% -22.49%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regulus Therapeutics 2.07 0 0% 155.87%
Revance Therapeutics 14.33 0.51 3.69% -52.85%
United Therapeutics 238.00 2.36 1.00% 29.12%
Immunic Inc. 3.47 0 0% -73.89%
Xoma 20.84 -1.44 -6.46% -37.42%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Immunic Inc.
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.